In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan

Journal of Infection and Chemotherapy

Volumn 20, Issue 2, 2014, Pages 77-80

  Ikematsu, Hideyuki ^a,b   Kawai, Naoki ^b   Iwaki, Norio ^b   Kashiwagi, Seizaburo ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b Japan Physician's Association   (Japan)

Author keywords

50 Inhibitory concentration; Influenza; Laninamivir; Oseltamivir; Peramivir; Zanamivir

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; INFLUENZA VIRUS HEMAGGLUTININ; LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE;

ADULT; AGE DISTRIBUTION; ANIMAL CELL; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; ENZYME INHIBITION; EPIDEMIC; FEMALE; GENE SEQUENCE; HUMAN; IC 50; IN VITRO STUDY; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; JAPAN; KIDNEY CELL; MALE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEASON; VIRAL PHENOMENA AND FUNCTIONS; VIRUS GENE; VIRUS ISOLATE; VIRUS ISOLATION; VIRUS RESISTANCE; VIRUS TYPING; 50% INHIBITORY CONCENTRATION; ADOLESCENT; AGED; ANIMAL; CHILD; DOG; DRUG ANTAGONISM; DRUG EFFECT; INFANT; INFLUENZA; ISOLATION AND PURIFICATION; MDCK CELL LINE; MIDDLE AGED; ORTHOMYXOVIRUS; PRESCHOOL CHILD; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

50% INHIBITORY CONCENTRATION; INFLUENZA; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DOGS; ENZYME INHIBITORS; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA, HUMAN; INHIBITORY CONCENTRATION 50; JAPAN; MADIN DARBY CANINE KIDNEY CELLS; MALE; MIDDLE AGED; NEURAMINIDASE; ORTHOMYXOVIRIDAE; YOUNG ADULT;

EID: 84903746265     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.07.002     Document Type: Article

References (16)

1. Kawai N, Ikematsu H, Iwaki N, Satoh I, Kawashima T, Maeda T, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: A multicenter study from Japan of the 2002e2003 influenza season. Clin Infect Dis 2005;40:1309-1316 (Pubitemid 40570241)
2. Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: A Japanese multicenter study of the 2003e2004 and 2004e2005 influenza seasons. Clin Infect Dis 2006;43:439-444 (Pubitemid 44157151)
3. Yates PJ, Mehta N, Horton J, Tisdale M. Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza. Antimicrob Agents Chemother 2013. http://dx.doi.org/10. 1128/AAC.02145-12
4. Sugaya N, Ohashi Y. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection. Antimicrob Agents Chemother 2010;54:2575-82
5. Kashiwagi S, Yoshida S, Yamaguchi H, Niwa S, Mitsui N, Tanigawa M. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents 2012;40: 381-8
6. Kohno S, Yen MY, Cheong HJ, Hirotsu N, Ishida T, Kadota J, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011;55:5267-76
7. Transmission dynamics and impact of pandemic influenza A (H1N1) 2009 virus. Wkly Epidemiol Rec 2009;46:481-4. http://www.who.int/wer/2009/ wer8446.pdf
8. National Institute of Infectious Diseases: http://www.nih.go.jp/niid/ja/ fromidsc.html
9. Ikematsu H, Kawai N, Kashiwagi S. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan. J Infect Chemother 2012;18: 529-33
10. Stockton J, Ellis JS, Saville M, Clewley JP, Zambon MC. Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol 1998;36:2990-5 (Pubitemid 28429426)
11. Dapat IC, Dapat C, Baranovich T, Suzuki Y, Kondo H, Shobugawa Y, et al. Genetic characterization of human influenza viruses in the pandemic (2009e 2010) and post-pandemic (2010-2011) periods in Japan. PLoS ONE 2012;7: e36455
12. Konno F, Arai T, Zhang MR, Hatori A, Yanamoto K, Ogawa M, et al. Radiosyntheses of two positron emission tomography probes:[11C]Oseltamivir and its active metabolite [11C]Ro 64-0802. Bioorg Med Chem Lett 2008 15;18(4): 1260-3 (Pubitemid 351226552)
13. Zambon M, Hayden FG. Global neuraminidase inhibitor susceptibility network. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001;49:147-56 (Pubitemid 32322468)
14. World Health Organization. Meeting of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 2012;39:369-80
15. Kawai N, Hirotsu N, Ikematsu H. Influenza manual e 2011-2012 season. JJPA 2012;27(Suppl.):1-50 (in Japanese)
16. Barrett S, Mohr PG, Schmidt PM, McKimm-Breschkin JL. Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. PLoS ONE 2011: e23627.